

References

I-11

1. Rothrock J, Bloudek L, Houle T, et al. Real world economic impact of onabotulinumtoxinA in patients with chronic migraine. *Headache*. 2014;54(10):1565-1573.
2. Naumann M, Boo L, Ackerman A, et al. Immunogenicity of botulinum toxins. *J Neural Transm*. 2013;120(2):275-290.
3. Ramachandran R, Yaksh T. Therapeutic use of botulinum toxin in migraine: Mechanisms of action. *Br J Pharmacol*. 2014;171(18):4177-4192.
4. OH HM, Chung M. Botulinum toxin for neuropathic pain: A review of the literature. *Toxins (Basel)*. 2015;7(8):3127-3154.
5. Headache Classification Committee of the International Headache Society (IHS). The International Headache Society 3rd edition (beta version). 2013;33(9):629-808.
6. Lakraj A, Moghimi N, Jabbari B. Sialorrhea: Anatomy, pathophysiology and treatment with emphasis on the role of botulinum toxins. *Toxins(Basel)*. 2013;5(5):1010-1031.
7. Persaud, R, Garas G, Silva S, et al. An evidence-based review of botulinum toxin (Botox) applications in non-cosmetic head and neck conditions. *J R Soc Med Sh Rep* 2013;4:10.
8. Srivanichapoom P, Pandey S, Hallett M. Drooling in Parkinson's disease: A review. Parkinson's disease (PD) is a neurodegenerative disease causing both motor and non-motor symptoms. *Parkinsonism Relat Disord*. 2014;20(11):1109-1118.
9. Strobl W, Theologis T, Brunner R, et al. Best clinical practice in botulinum toxin treatment for children with cerebral palsy. 2015;7(5):1629-1648.
10. Elovic EP, Munin MC, Kanovsky P, et al: Randomized, placebo-controlled trial of incobotulinumtoxinA for upper-limb post-stroke spasticity. *Muscle Nerve*. 2016; 53(3):415-421.
11. Esquenazi A, Alfaro A, Ayyoub Z, et al. OnabotulinumtoxinA for lower limb spasticity: Guidance from a Delphi panel approach. *PM&R*. 2017;9(10):960-968.
12. Aurora S, Dodick D, Diener H, et al., OnabotulinumtoxinA for chronic migraine: Efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program. *Acta Neurol Scand*. 2014;129:61-70.
13. Ranoux D, Martine G, Espagne-Debreuilh G, et al. OnabotulinumtoxinA injections in chronic migraine, targeted to sites of pericranial myofascial pain: an observational, open label, real life cohort study. *J Headache Pain*. 2017;18:75-83.

14. Pellegrini M, Schiavi C, Taroni L, et al. Ocular surface status in patients with hemifacial spasm under long-lasting treatment with botulinum A toxin: A comparative fellow eye study. *Indian J Ophthalmol.* 2019;67:1405-9.
15. Arai S, Fukase Y, Okii A, Suzukamo Y & Suga T. Selection process for botulinum toxin injections in patients with chronic-stage hemiplegic stroke: a qualitative study. *BMC Med Inform and Decis Mak.* 2019;19:280-291.
16. Yana M, Tutuola F, Westwater-Wood S, & Kavlak E. The efficacy of botulinum toxin A lower limb injections in addition to physiotherapy approaches in children with cerebral palsy: A systematic review. 2019;44:175-189.
17. Chen J & Kuo H. Clinical application of intravesical botulinum toxin type A for overactive bladder and interstitial cystitis. *Investig Clin Urol.* 2020;61:S33-42.
18. Hayes, Inc. Hayes Health Technology Assessment. Botulinum Toxin Treatment for Migraine Headache. Lansdale, PA: Hayes, Inc.; September 2021.
19. Hayes, Inc. Hayes Evidence Analysis Research Brief. Botulinum Toxin for Treatment of Pain Associated with Temporomandibular Disorders. Lansdale, PA: Hayes, Inc.; May 2021.
20. AbobotulinumtoxinA In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated March 25, 2019.
21. IncobotulinumtoxinA In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated March 25, 2019.
22. OnabotulinumtoxinA In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated March 25, 2019.
23. RimabotulinumtoxinB In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated March 25, 2019.
24. Clinical Pharmacology™ 2022. Tampa FL: Gold Standard, Inc. AbobotulinumtoxinA.
25. Clinical Pharmacology™ 2022. Tampa FL: Gold Standard, Inc. IncobotulinumtoxinA.
26. Clinical Pharmacology™ 2022. Tampa FL: Gold Standard, Inc. OnabotulinumtoxinA.
27. Clinical Pharmacology™ 2022. Tampa FL: Gold Standard, Inc. RimabotulinumtoxinB.
28. Lexi-Drugs. Hudson, OH: Lexicomp, 2022.
29. Lexi-Drugs. Hudson, OH: Lexicomp, 2022.
30. Lexi-Drugs. Hudson, OH: Lexicomp, 2022.

31. Lexi-Drugs. Hudson, OH: Lexicomp, 2022.
32. Micromedex DrugDex Compendium®. 2022. AbobotulinumtoxinA.
33. Micromedex DrugDex Compendium®. 2022. IncobotulinumtoxinA.
34. Micromedex DrugDex Compendium®. 2022. OnabotulinumtoxinA.
35. Micromedex DrugDex Compendium®. 2022. RimabotulinumtoxinB.
36. Dysport® (abobotulinumtoxinA) for injection, for intramuscular use [package insert]. Ipsen Biopharm, Ltd. Cambridge, MA. Revised 7/2020.
37. Xeomin® (incobotulinumtoxinA) for injection, for intramuscular or intraglandular use [package insert]. Merz Pharmaceuticals, LLC. Raleigh, NC. Revised 8/2021.
38. Botox® (onabotulinumtoxinA) for injection, for intramuscular intradetrusor, or intradermal use [package insert]. Allergan, Inc. Madison, NJ. Revised 7/2021.
39. Myobloc® (rimabotulinumtoxinB) injection, for intramuscular or intraglandular use [package insert]. Solstice Neurosciences, Inc. Louisville, KY. Revised 3/2021.